Bruker price target lowered to $50 from $61 at BofA

TipRanks

Fri, Jun 27, 2025, 10:25 AM 1 min read

BofA lowered the firm’s price target on Bruker (BRKR) to $50 from $61 and keeps a Buy rating on the shares. The firm is updating its price targets for stocks under its coverage in the Life Sciences & Diagnostic Tools, LSTs, sector, the analyst tells investors. The firm notes LSTs remain under pressure as uncertainty persists with the macro environment and U.S. government policies. Recent weeks, however, have seen some signs of improvement as tariff concerns have cools slightly, the firm adds.

• Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions

• Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See Insiders’ Hot Stocks on TipRanks >>

Read More on BRKR:

Disclaimer & DisclosureReport an Issue

• NIH directs staff not to end any extra research projects for now, NY Times says

• Bruker’s Growth Potential Driven by Innovations and Strategic Cost Management

• Bruker acquires biocrates life sciences, terms undisclosed

• Bruker launches new timsUltra AIP system

• Bruker unveils new proteoElute nanoLC system, PepSep Advanced nLC columns